Evidence map›Paper›PMID 34168992›Full record

ArticleFrontiers in oncology2021

US-Based Deep Learning Model for Differentiating Hepatocellular Carcinoma (HCC) From Other Malignancy in Cirrhotic Patients.

Hang Zhou, Tao Jiang, Qunying Li, Chao Zhang, Cong Zhang, Yajing Liu, Jing Cao, Yu Sun, Peile Jin, Jiali Luo and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Hang ZhouDepartment of Ultrasound, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Tao JiangDepartment of Ultrasound, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Qunying LiDepartment of Ultrasound, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Chao ZhangDepartment of Ultrasound, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Cong ZhangDepartment of Ultrasound, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yajing LiuDepartment of Ultrasound, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jing CaoDepartment of Ultrasound, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yu SunDepartment of Ultrasound, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Peile JinDepartment of Ultrasound, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jiali LuoDepartment of Ultrasound, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Minqiang PanDepartment of Ultrasound, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Pintong HuangDepartment of Ultrasound, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Second Affiliated Hospital of Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim was to build a predictive model based on ultrasonography (US)-based deep learning model (US-DLM) and clinical features (Clin) for differentiating hepatocellular carcinoma (HCC) from other malignancy (OM) in cirrhotic patients. 112 patients with 120 HCCs and 60 patients with 61 OMs were included. They were randomly divided into training and test cohorts with a 4:1 ratio for developing and evaluating US-DLM model, respectively. Significant Clin predictors of OM in the training cohort were combined with US-DLM to build a nomogram predictive model (US-DLM+Clin). The diagnostic performance of US-DLM and US-DLM+Clin were compared with that of contrast enhanced magnetic resonance imaging (MRI) liver imaging and reporting system category M (MRI LR-M). US-DLM was the best independent predictor for evaluating OMs, followed by clinical information, including high cancer antigen 199 (CA199) level and female. The US-DLM achieved an AUC of 0.74 in the test cohort, which was comparable with that of MRI LR-M (AUC=0.84, p=0.232). The US-DLM+Clin for predicting OMs also had similar AUC value (0.81) compared with that of LR-M+Clin (0.83, p>0.05). US-DLM+Clin obtained a higher specificity, but a lower sensitivity, compared to that of LR-M +Clin (Specificity: 82.6%

Indexed as

cirrhosiscontrast enhanced magnetic resonance imagingdeep learning—artificial neural networkhepatocellular carcinomaultrasonography

Identifiers

PMID34168992
PMCPMC8217663
OpenAlexW3169938279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.